Shenzhen Salubris Pharmaceuticals Co., Ltd.

SZSE:002294.SZ

29.64 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 3,365.3433,482.0113,058.3922,738.5624,470.4664,651.8764,153.7773,833.493,477.6932,882.6452,327.4841,828.8821,474.8851,297.767849.598527.17349.435203.144
Cost of Revenue 1,065.462993.612793.279847.697964.366943.673785.056949.879912.288764.854564.619465.422559.862555.592376.41259.36185.872107.099
Gross Profit 2,299.8812,488.3992,265.1131,890.8653,506.13,708.2033,368.7212,883.6112,565.4042,117.7911,762.8641,363.46915.022742.175473.187267.809163.56396.045
Gross Profit Ratio 0.6830.7150.7410.690.7840.7970.8110.7520.7380.7350.7570.7460.620.5720.5570.5080.4680.473
Reseach & Development Expenses 376.371533.75357.368371.195763.497407.477327.054224.273175.765121.18127.608112.3287766.5960000
General & Administrative Expenses 102.80962.3760.73848.13851.11452.46753.09843.56744.65627.04822.52732.83216.41112.55953.48229.88721.1613.427
Selling & Marketing Expenses 606.6861,094.4271,035.866899.1981,576.2691,345.6441,155.732852.075775.144713.013594.467453.183332.303256.385168.877111.465.16144.088
SG&A 1,267.8291,156.7971,096.604947.3361,627.3831,398.1111,208.83895.641819.8740.061616.994486.014348.715268.945222.359141.28786.32157.515
Other Expenses 7.616165.366233.995203.955229.045-13.7160.722.04813.28910.90715.06520.8078.3872.7774.5363.1050.616-0.664
Operating Expenses 1,651.8161,855.9131,687.9681,522.4862,619.9252,014.8851,710.711,279.381,106.622943.704809.209647.532461.594344.709223.013141.70986.58657.685
Operating Income 655.976727.436586.195348.723846.0811,719.9621,714.6231,630.8481,478.4781,207.186967.764729.794466.774412.72245.703123.52776.15137.331
Operating Income Ratio 0.1950.2090.1920.1270.1890.370.4130.4250.4250.4190.4160.3990.3160.3180.2890.2340.2180.184
Total Other Income Expenses Net -14.215-13.71113.647-22.4785.265-13.7160.720.29513.0110.1778.6720.4977.7872.7683.650.5330.438-0.664
Income Before Tax 641.761713.725599.84256.743851.3461,706.2461,715.3231,650.4751,491.4881,217.363976.434750.288474.56415.488249.352126.63276.5936.667
Income Before Tax Ratio 0.1910.2050.1960.0210.190.3670.4130.4310.4290.4220.420.410.3220.320.2930.240.2190.18
Income Tax Expense 60.93279.50771.526.608169.505251.665278.442260.436221.814173.979143.174114.73669.11259.97833.6739.693.4522.428
Net Income 580.066637.091533.72760.865715.2011,458.2231,451.8871,396.4141,265.921,042.297830.417635.168405.249355.314215.747116.94273.13834.239
Net Income Ratio 0.1720.1830.1750.0220.160.3130.350.3640.3640.3620.3570.3470.2750.2740.2540.2220.2090.169
EPS 0.520.580.50.0590.691.391.391.331.2110.790.610.390.340.250.150.0930.052
EPS Diluted 0.520.580.50.0590.691.391.391.331.2110.790.610.390.340.250.150.0930.052
EBITDA 1,050.5261,046.421914.637377.1031,096.7171,813.5741,855.3231,774.4051,527.5011,237.4291,018.969757.425485.162435.395263.778136.72384.20341.802
EBITDA Ratio 0.3120.3140.350.2170.2480.4050.440.4620.4430.4310.4380.4190.3340.3420.3150.2610.2410.209